Journal
Journal of Clinical Oncology
Publication Date
1-20-2024
Volume
42
Issue
3
First Page
258
Last Page
265
Document Type
Open Access Publication
DOI
10.1200/JCO.22.02636
Rights and Permissions
Sweeney CJ, Hainsworth JD, Bose R, Burris HA, Kurzrock R, Swanton C, Friedman CF, Spigel DR, Szado T, Schulze K, Price R, Malato J, Lo AA, Levy J, Wang Y, Yu W, Meric-Bernstam F. MyPathway Human Epidermal Growth Factor Receptor 2 Basket Study: Pertuzumab + Trastuzumab Treatment of a Tissue-Agnostic Cohort of Patients With Human Epidermal Growth Factor Receptor 2-Altered Advanced Solid Tumors. J Clin Oncol. 2024 Jan 20;42(3):258-265. doi: 10.1200/JCO.22.02636. © 2023 by American Society of Clinical Oncology. Creative Commons Attribution Non-Commercial No Derivatives 4.0 License: http://creativecommons.org/licenses/by-nc-nd/4.0/
Recommended Citation
Sweeney, Christopher J; Bose, Ron; and et al., "MyPathway human epidermal growth factor receptor 2 basket study: Pertuzumab + trastuzumab treatment of a tissue-agnostic cohort of patients with human epidermal growth factor receptor 2-altered advanced solid tumors." Journal of Clinical Oncology. 42, 3. 258 - 265. (2024).
https://digitalcommons.wustl.edu/oa_4/3255
Department
ICTS (Institute of Clinical and Translational Sciences)
Additional Links
Supplemental material is available for this article at publisher site.
